BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18374225)

  • 1. (18)F-fluorodeoxyglucose positron emission tomography-based assessment of local failure patterns in non-small-cell lung cancer treated with definitive radiotherapy.
    Sura S; Greco C; Gelblum D; Yorke ED; Jackson A; Rosenzweig KE
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1397-402. PubMed ID: 18374225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer.
    Ashamalla H; Rafla S; Parikh K; Mokhtar B; Goswami G; Kambam S; Abdel-Dayem H; Guirguis A; Ross P; Evola A
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1016-23. PubMed ID: 15979817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer.
    Nestle U; Kremp S; Schaefer-Schuler A; Sebastian-Welsch C; Hellwig D; Rübe C; Kirsch CM
    J Nucl Med; 2005 Aug; 46(8):1342-8. PubMed ID: 16085592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (18)F-FDG PET-CT simulation for non-small-cell lung cancer: effect in patients already staged by PET-CT.
    Hanna GG; McAleese J; Carson KJ; Stewart DP; Cosgrove VP; Eakin RL; Zatari A; Lynch T; Jarritt PH; Young VA; O'Sullivan JM; Hounsell AR
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):24-30. PubMed ID: 19665324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
    Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-fluorodeoxyglucose positron emission tomography/computed tomography-based radiotherapy target volume definition in non-small-cell lung cancer: delineation by radiation oncologists vs. joint outlining with a PET radiologist?
    Hanna GG; Carson KJ; Lynch T; McAleese J; Cosgrove VP; Eakin RL; Stewart DP; Zatari A; O'Sullivan JM; Hounsell AR
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1040-51. PubMed ID: 20350798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of [18F]fluorodeoxyglucose PET-CT staging on treatment planning in radiotherapy incorporating elective nodal irradiation for non-small-cell lung cancer: a prospective study.
    Kolodziejczyk M; Kepka L; Dziuk M; Zawadzka A; Szalus N; Gizewska A; Bujko K
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1008-14. PubMed ID: 20656419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.
    Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1432-41. PubMed ID: 16125870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of FDG-PET on computed tomography-based radiotherapy planning for locally recurrent nasopharyngeal carcinoma.
    Zheng XK; Chen LH; Wang QS; Wu HB; Wang HM; Chen YQ; Yan WP; Li QS; Xu YK
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1381-8. PubMed ID: 17869450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is image registration of fluorodeoxyglucose-positron emission tomography/computed tomography for head-and-neck cancer treatment planning necessary?
    Fried D; Lawrence M; Khandani AH; Rosenman J; Cullip T; Chera BS
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):748-54. PubMed ID: 22414285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical study of shrinking field radiation therapy based on (18)F-FDG PET/CT for stage III non-small cell lung cancer.
    Ding X; Li H; Wang Z; Huang W; Li B; Zang R; Sun H; Yi Y
    Technol Cancer Res Treat; 2013 Jun; 12(3):251-7. PubMed ID: 23289475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A study on the application of 18F-FDG-PET-CT for the radiotherapy of patients with stage III non-small cell lung cancer].
    Shandan ; Han B; Pan H; Yu L; Wang R
    Zhongguo Fei Ai Za Zhi; 2010 Jul; 13(7):700-5. PubMed ID: 20673486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of FDG PET/CT on delineation of the gross tumor volume for radiation planning in non-small-cell lung cancer.
    Spratt DE; Diaz R; McElmurray J; Csiki I; Duggan D; Lu B; Delbeke D
    Clin Nucl Med; 2010 Apr; 35(4):237-43. PubMed ID: 20305410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
    Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
    Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer.
    Vanuytsel LJ; Vansteenkiste JF; Stroobants SG; De Leyn PR; De Wever W; Verbeken EK; Gatti GG; Huyskens DP; Kutcher GJ
    Radiother Oncol; 2000 Jun; 55(3):317-24. PubMed ID: 10869746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET).
    Erdi YE; Rosenzweig K; Erdi AK; Macapinlac HA; Hu YC; Braban LE; Humm JL; Squire OD; Chui CS; Larson SM; Yorke ED
    Radiother Oncol; 2002 Jan; 62(1):51-60. PubMed ID: 11830312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): primary analysis of Radiation Therapy Oncology Group (RTOG) 0515.
    Bradley J; Bae K; Choi N; Forster K; Siegel BA; Brunetti J; Purdy J; Faria S; Vu T; Thorstad W; Choy H
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):435-41.e1. PubMed ID: 21075551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of hybrid fluorodeoxyglucose positron-emission tomography/computed tomography on radiotherapy planning in esophageal and non-small-cell lung cancer.
    Gondi V; Bradley K; Mehta M; Howard A; Khuntia D; Ritter M; Tomé W
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):187-95. PubMed ID: 17189070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target volume definition for 18F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer.
    Nestle U; Schaefer-Schuler A; Kremp S; Groeschel A; Hellwig D; Rübe C; Kirsch CM
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):453-62. PubMed ID: 17058078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study.
    van Der Wel A; Nijsten S; Hochstenbag M; Lamers R; Boersma L; Wanders R; Lutgens L; Zimny M; Bentzen SM; Wouters B; Lambin P; De Ruysscher D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):649-55. PubMed ID: 15708242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.